ENANTA PHARMACEUTICALS INC
ENTANasdaq
$13.74
↑ +4.2%Jul 17 close · end-of-day
Price
1Y↑ +93.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$399.0M
Enterprise Value
$235.2M
P/E
—
P/S
5.8
P/B
3.4
EV/EBITDA
—
PEG
—
FCF Yield
-2.4%
Dividend Yield
—
Revenue (TTM)
$69.2M
Net Income (TTM)
-$62.0M
Free Cash Flow (TTM)
-$9.6M
Gross Margin
—
Operating Margin
-87.2%
Net Margin
-89.6%
ROE
-53.2%
ROIC
—
Debt / Equity
—
Net Cash
$163.8M
Return 1Y
+90.0%
Company profile
Enanta Pharmaceuticals, Inc. discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus.
- CEO
- Jay R. Luly
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 160
- Headquarters
- Massachusetts
- Website
- enanta.com
Management & directors
- Kieffer Tara LynnChief Product Strategy Officer
- Kowalsky Matthew PaulChief Legal Officer
- Luly Jay R.President and CEO
- Luu BrendanChief Business Officer
- Or Yat SunChief Scientific Officer
- Rottinghaus Scott T.Chief Medical Officer
- Capps Kathleen S.See Remarks
- Trout Harry R. IiiSee Remarks
Roles derived from SEC Form 4 filings.
Earnings
ENTA Q2 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$17.2M↑ +15.0%
Diluted EPS-$0.45↓ -57.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $122.5M | $97.1M | $86.2M | $79.2M | $67.6M | $65.3M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$41.6M | -$109.6M | -$123.8M | -$137.2M | -$121.7M | -$85.3M |
| Net income | -$36.2M | -$79.0M | -$121.8M | -$133.8M | -$116.0M | -$81.9M |
| Diluted EPS | -$1.81 | -$3.92 | -$5.91 | -$6.38 | -$5.48 | -$3.84 |
| Operating cash flow | $7.1M | -$70.0M | -$84.8M | -$103.2M | -$78.8M | -$19.3M |
| Free cash flow | $5.6M | -$70.7M | -$86.9M | -$112.2M | -$96.7M | -$32.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -34.0% | -112.9% | -143.7% | -173.2% | -179.9% | -130.7% |
| Net margin | -29.5% | -81.4% | -141.3% | -169.0% | -171.6% | -125.4% |
| Line item | Q3 '24 | Q4 '24 | Q1 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.0M | $14.6M | $17.0M | $14.9M | $18.3M | $15.1M | $18.6M | $17.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$24.2M | -$29.9M | -$23.5M | -$24.5M | -$18.9M | -$18.4M | -$11.3M | -$11.9M |
| Net income | -$22.7M | -$28.8M | -$22.3M | -$22.6M | -$18.3M | -$18.7M | -$11.9M | -$13.1M |
| Diluted EPS | -$1.07 | -$1.36 | -$1.05 | -$1.06 | -$0.85 | -$0.88 | -$0.42 | -$0.45 |
| Operating cash flow | -$14.8M | -$10.4M | -$16.8M | -$13.5M | $17.5M | -$6.5M | -$11.7M | -$7.2M |
| Free cash flow | -$21.3M | -$19.4M | -$25.5M | -$16.0M | $17.4M | -$7.9M | -$11.8M | -$7.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -134.6% | -204.4% | -138.8% | -164.3% | -103.2% | -121.6% | -60.5% | -69.1% |
| Net margin | -126.1% | -197.3% | -131.4% | -151.7% | -99.7% | -123.6% | -64.1% | -76.3% |
Company news
Jun 24, 2026
May 28, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-02-12 | Luly Jay R.· President and CEO | Tax withholding | 6,155 | $14.25 | $87,708.75 | filing |
| 2026-02-12 | Or Yat Sun· Chief Scientific Officer | Tax withholding | 3,413 | $14.25 | $48,635.25 | filing |
| 2026-02-12 | Rottinghaus Scott T.· Chief Medical Officer | Tax withholding | 3,413 | $14.25 | $48,635.25 | filing |
| 2026-02-12 | Kieffer Tara Lynn· Chief Product Strategy Officer | Tax withholding | 3,257 | $14.25 | $46,412.25 | filing |
| 2026-02-12 | Luu Brendan· Chief Business Officer | Tax withholding | 3,257 | $14.25 | $46,412.25 | filing |
| 2026-02-12 | Kowalsky Matthew Paul· Chief Legal Officer | Tax withholding | 1,902 | $14.25 | $27,103.50 | filing |
| 2026-02-12 | Rottinghaus Scott T.· Chief Medical Officer | Award | 1,650 | $0.00 | $0.00 | filing |
| 2026-02-12 | Rottinghaus Scott T.· Chief Medical Officer | Award | 5,225 | $0.00 | $0.00 | filing |
| 2026-02-12 | Or Yat Sun· Chief Scientific Officer | Award | 1,650 | $0.00 | $0.00 | filing |
| 2026-02-12 | Or Yat Sun· Chief Scientific Officer | Award | 5,225 | $0.00 | $0.00 | filing |
| 2026-02-12 | Luly Jay R.· President and CEO | Award | 4,800 | $0.00 | $0.00 | filing |
| 2026-02-12 | Luly Jay R.· President and CEO | Award | 15,200 | $0.00 | $0.00 | filing |
| 2026-02-12 | Kowalsky Matthew Paul· Chief Legal Officer | Award | 1,318 | $0.00 | $0.00 | filing |
| 2026-02-12 | Kowalsky Matthew Paul· Chief Legal Officer | Award | 4,175 | $0.00 | $0.00 | filing |
| 2026-02-12 | Luu Brendan· Chief Business Officer | Award | 1,575 | $0.00 | $0.00 | filing |
| 2026-02-12 | Luu Brendan· Chief Business Officer | Award | 4,987 | $0.00 | $0.00 | filing |
| 2026-02-12 | Kieffer Tara Lynn· Chief Product Strategy Officer | Award | 1,575 | $0.00 | $0.00 | filing |
| 2026-02-12 | Kieffer Tara Lynn· Chief Product Strategy Officer | Award | 4,987 | $0.00 | $0.00 | filing |
| 2025-12-05 | Luly Jay R.· President and CEO | Sale | 4,743 | $14.23 | $67,492.89 | filing |
| 2025-12-05 | Or Yat Sun· Chief Scientific Officer | Sale | 2,390 | $14.23 | $34,009.70 | filing |
| 2025-12-05 | Kieffer Tara Lynn· Chief Product Strategy Officer | Sale | 2,106 | $14.23 | $29,968.38 | filing |
| 2025-12-05 | Luu Brendan· Chief Business Officer | Sale | 1,394 | $14.23 | $19,836.62 | filing |
| 2025-12-05 | Rottinghaus Scott T.· Chief Medical Officer | Sale | 798 | $14.23 | $11,355.54 | filing |
| 2025-12-05 | Trout Harry R. III· See Remarks | Sale | 542 | $14.23 | $7,712.66 | filing |
| 2025-12-05 | Capps Kathleen S.· See Remarks | Sale | 323 | $14.23 | $4,596.29 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.